Acton Pharma gets USFDA nod for an inhaled steroid to treat asthma

By Admin
Acton Pharmaceuticals, Inc Friday said it has secured approval from the U.S. Food and Drug Administration of its supplemental New Drug Application for...

Acton Pharmaceuticals, Inc Friday said it has secured approval from the U.S. Food and Drug Administration of its supplemental New Drug Application for an inhaled steroid to treat asthma, the news reports said.

The FDA approved the application for AEROSPAN, an oral corticosteroid used in treating asthma in adults and kids six and under.

Post getting the approval, the respiratory therapeutics company now plans to launch AEROSPAN into $8.3 billion inhaled steroid market in early 2013, the company said.

Acton Pharma bought AEROSPAN new drug application under the licensing agreement with Forest Laboratories, Inc in 2009.

Acton President Daniel Kreisler said, “Acton anticipates commercial launch of AEROSPAN in the first quarter of 2013 as we build out our sales and marketing infrastructure and evaluate strategic partnerships.” Mr. Kreisler also said, “Our ongoing commercial preparations include building product inventory as well as finalizing the introduction of Aerospan to manage care plans and initiation of pre-launch marketing activities.”

As per the Center for Disease Control, there are more than 24 million Americans with asthma and the disease is the cause for nearly 2 million emergency visits each and $11.5 billion in healthcare costs.

Acton Pharmaceuticals, Inc is a respiratory specialty pharmaceutical company. It focuses on acquisition, development, and commercialization of products to treat allergic, pulmonary, and other respiratory related diseases.

Share
Share

Featured Articles

Healthcare Digital news roundup: digital healthcare & AI

This week in Healthcare Digital, we looked at digital skills for healthcare leaders, medical technology & acoustic AI used in digital cough monitoring

Hospitals must embrace IoMT device security

As cybersecurity threats rise in the healthcare sector, hospitals must get serious about IoMT device protection, says Shankar Somasundaram, CEO of Asimily

Mental health support for working women and mothers

Dr. Kylie Bennett, Mental Health Program Director at Dialogue, is committed to supporting women in the workplace - especially Mothers - and their health

Digital evolution delivers better healthcare outcomes

Digital Healthcare

Hyfe AI uses acoustic AI in its digital cough monitoring

Technology & AI

Siemens: smart finance to help medical technology growth

Technology & AI